Summary
- Main use
- Intravenous nutrition (amino acids and calories); correction of fluid and electrolyte deficiencies
- Who uses it
- Adults · Children
- Adult dosage
- Administer this drug through a central vein. Determine the dose according to the patient's condition, energy expenditure, and metabolic requirements. ○ Adults -Dose: 0.16 g of nitrogen per kg of body weight per day (equivalent to 1 g of amino acids per kg of body weight per day)~0.35 g (equivalent to 2 g of amino acids per kg of body weight per day) -Maximum daily dose: 36 mL per kg of body weight (equivalent to 1.44 g of amino acids, 5.76 g of glucose, and 1.44 g of fat per kg of body weight) Depending on the patient's nutritional status and degree of catabolism, the required energy intake is 25 kcal~40 kcal per kg of body weight per day. ○Maximum infusion rate : 1.5 mL/hr per kg of body weight (equivalent to 0.06 g of amino acids, 0.24 g of glucose, and 0.06 g of fat per kg of body weight per hour)
- Children's dosage
- ○ Children -Dose: 0.35 g of nitrogen per kg of body weight per day (equivalent to 2 g of amino acids per kg of body weight per day)~0.45 g (equivalent to 3 g of amino acids per kg of body weight per day) Adjust the dose according to the child's age, nutritional status, and disease.
Ingredients
- Soybean Oil4g / 100mL
- L-Alanine0.828g / 100mL
- L-Arginine0.46g / 100mL
- Glycine0.412g / 100mL
- L-Histidine0.192g / 100mL
- L-Isoleucine0.24g / 100mL
- L-Leucine0.292g / 100mL
- L-Lysine Hydrochloride0.29g / 100mL
- L-Methionine0.16g / 100mL
- L-Phenylalanine0.224g / 100mL
- L-Proline0.272g / 100mL
- L-Serine0.2g / 100mL
- L-Threonine0.168g / 100mL
- L-Tryptophan0.072g / 100mL
- L-Tyrosine0.016g / 100mL
- L-Valine0.232g / 100mL
- Sodium Acetate Hydrate0.272g / 100mL
- Dibasic Potassium Phosphate0.2088g / 100mL
- Sodium Chloride0.0468g / 100mL
- Magnesium Chloride Hydrate0.0408g / 100mL
- Glucose Monohydrate17.6g / 100mL
- Calcium Chloride Hydrate0.0264g / 100mL
- Manufacturer
- JW Life Science Co., Ltd.
Efficacy & effects
Intravenous nutrition (amino acids and calories); correction of fluid and electrolyte deficiencies
View approved original textHide original text
This medication is used to effectively provide fluids, electrolytes, amino acids, and calories to patients who are unable to obtain nutrition orally or through the gastrointestinal tract. It helps improve the nutritional status of patients and maintain bodily functions.
Dosage and Administration
Adult dosage
Administer this drug through a central vein. Determine the dose according to the patient's condition, energy expenditure, and metabolic requirements. ○ Adults -Dose: 0.16 g of nitrogen per kg of body weight per day (equivalent to 1 g of amino acids per kg of body weight per day)~0.35 g (equivalent to 2 g of amino acids per kg of body weight per day) -Maximum daily dose: 36 mL per kg of body weight (equivalent to 1.44 g of amino acids, 5.76 g of glucose, and 1.44 g of fat per kg of body weight) Depending on the patient's nutritional status and degree of catabolism, the required energy intake is 25 kcal~40 kcal per kg of body weight per day. ○Maximum infusion rate : 1.5 mL/hr per kg of body weight (equivalent to 0.06 g of amino acids, 0.24 g of glucose, and 0.06 g of fat per kg of body weight per hour)
Children's dosage
○ Children -Dose: 0.35 g of nitrogen per kg of body weight per day (equivalent to 2 g of amino acids per kg of body weight per day)~0.45 g (equivalent to 3 g of amino acids per kg of body weight per day) Adjust the dose according to the child's age, nutritional status, and disease.
Precautions
This drug must be used under the direction of a physician. Caution is needed when administering this drug with calcium-containing medications intravenously. Specifically, mixing with Ceftriaxone can cause precipitation, so it should not be administered simultaneously using the same infusion device. If the same infusion line must be used, it should be thoroughly cleansed before and after the infusion. Premature infants or low-weight infants may not be able to adequately metabolize the lipid components of this drug, which can lead to elevated free fatty acid levels in the blood. Cases of death have been reported in premature infants with severe respiratory disorders when administered, so extreme caution is necessary. This drug should not be administered to certain patients. For example, patients with allergies to any components of this drug, those with abnormally high serum electrolyte concentrations, patients with severely impaired kidney or liver function, those with congenital amino acid metabolism disorders, metabolic acidosis or lactic acidosis, adrenal insufficiency, pulmonary edema or heart failure, severe sepsis or lipid metabolism disorders, severely coagulation-disordered patients, myocardial infarction patients, infants under 2 years of age, and those sensitive to soybean oil, soy, or peanuts. Additionally, in patients with hyponatremia or high serum osmolality, care should be taken when administering this drug, especially in those with hyperlipidemia or diabetic dyslipidemia, pancreatitis, or other lipid metabolism issues. Administering this drug in high doses or too rapidly can lead to adverse effects. During administration, acute reactions such as elevated body temperature, sweating, chills, headache, or respiratory distress can occasionally occur, and if these symptoms arise, administration must be stopped immediately. Prolonged administration may temporarily raise liver function test values and can rarely lead to hepatomegaly or jaundice and thrombocytopenia. When used in children, caloric, amino acid, electrolyte, and fluid requirements must be individually adjusted, and the patient's condition should be closely monitored during intravenous administration. During central venous administration, there is a risk of infection, so strict aseptic conditions must be maintained, and administering hypertonic solutions in peripheral veins may cause venous irritation. Regular checks of blood glucose, electrolytes, fluid balance, acid-base balance, liver function, and blood counts should be conducted during administration, and if hyperglycemia occurs, administration speed may need to be adjusted or insulin therapy might be required. Serum triglyceride levels must be periodically checked and managed to avoid exceeding normal values; daily tests should be conducted if lipid metabolism disorders are suspected. When mixing with other drugs, compatibility must be verified, and it is essential not to use the same infusion equipment if administered concurrently with blood, as agglutination reactions can occur. The safety of this drug in pregnant or nursing women has not been established, and it should only be administered when the benefits of treatment outweigh the risks. For newborns, infants, and children, it is recommended to use pediatric amino acid preparations to meet specific metabolic needs. Elderly patients may have reduced bodily functions, so careful adjustment of administration speed and dosage is necessary. In cases of overdose, symptoms of acidosis, fluid overload, hyperglycemia, vomiting, chills, liver dysfunction, hyperlipidemia, and others may arise. Administration must be stopped immediately, and treatment such as dialysis may be necessary. Finally, precautions should be taken during administration to ensure no air enters the container to prevent air embolism, and continuous connections should be avoided.
Side effects
- increased body temperature
- sweating
- chills
- headache
- respiratory distress
- ALP increase
- transaminase increase
- elevated bilirubin levels
- hepatomegaly
- jaundice
Show 12 moreCollapse
- thrombocytopenia
- fever
- skin rash
- anaphylactic reaction
- vomiting
- nausea
- hemodynamic instability
- liver dysfunction
- edema
- bleeding disorder
- hyperlipidemia
- hypersensitivity reaction
Not everyone experiences these, and they can vary from person to person.
Storage
This drug should be stored in a sealed container to avoid contact with air and must be kept from freezing. Additionally, it is recommended to store it in a cool place below 25 degrees to maintain its effectiveness.
Appearance and packaging
Appearance
A transparent plastic bag for infusion containing three compartments separated by two membranes, filled with solutions A, B, and C. Solution A is a white emulsion, a fluid dosage form.
Package unit
1000 mL, 1450 mL
Questions about this medicine
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.